Search In this Thesis
   Search In this Thesis  
العنوان
Trial for Preparation of Inactivated Vaccine from Egyptian Avian Influenza Virus Isolate /
المؤلف
El-Qrsh, Mohamed Fekry El-Bayomi.
هيئة الاعداد
باحث / Mohamed Fekry El-Bayomi El-Qrsh
مشرف / Ahmed Abd El-Samie Hassan Ali
مشرف / Fatma M. Abd Allah
مشرف / Fatma M. Abd Allah
الموضوع
Veterinary Virology. Influenza viruses.
تاريخ النشر
2014.
عدد الصفحات
90 p. :
اللغة
الإنجليزية
الدرجة
ماجستير
التخصص
البيطري
تاريخ الإجازة
1/1/2014
مكان الإجازة
جامعة الزقازيق - كلية الطب البيطرى - Department of Virology
الفهرس
Only 14 pages are availabe for public view

from 120

from 120

Abstract

The inactivation is done by using Binnary Ethline Amine (BEI) rather than all other inactivators due to its ability to inactivate the RNA with no affection on the outer protein which contain the spikes that is responsible for the virus antigenicity so the antibody titer will be high. The allantoic fluid is mixed with BEI for 24 hours and samples taken at (2,4,6,8 and24)to examine the virus viability via injection of 11 days old SPF with 0.2 ml at allantoic fluid then examine the embryos after 5 days then mixing of the finally prepared inactivated virus with mineral oil (Montanid ISA 206) that is available in the affordable price in the Egyptian market by weight \ weight then mixing using vortex, adding of saponine and merthiolate as immunostimulant and preservative respectively so the vaccine is finally prepared and the vaccine had examined for quality control by physical evaluation of the prepared vaccine for good mixing and safety test for the vaccine even in double dose and sterility test for bacterial, fungal and mycoplasma contamination then detect potency of the vaccine by challenge test by prepare five groups each group containing ten chicks Group 1 Were used as positive control that clinically infected by AIAV at 28 days old with out vaccination, Group 2 were used as negative control in which it treated by prepared vaccine at 9 days old without virus challenge, Group 3 Were treated by AIAV vaccine that prepared in lab. by 0.5 ml that contains 108 EID50 /ml at 9 days old and then infected by an AIAV H5N1 at 28 days, Group 4 were treated by commercial imported AIAV vaccine (H5N1 subtype Egy/PR 8-1 strain) by 0.5 ml that contains 108.5 EID50/ml at 9 days old and then infected by an AIAV challenge at 28 days and Group 5 used as a blank.